Reslizumab therapy in patients with EGPA
| Reference | Study design | Number of patients | Dose and route of administration | Results |
|---|---|---|---|---|
| Kent et al. [62], 2020 | Case series | 9 | 3 mg IV/kg every 4 weeks | CS reduction2 Patients completely withdraw from CSNo significant changes were observed in BVAS and lung function |
| Manka et al. [63], 2021 | Prospective open-label pilot study | 10 | 3 mg IV/kg every 4 weeks | Reslizumab was safe and well toleratedCS reductionNo significant change in the asthma quality of life questionnaireDecrease in blood eosinophil countImprovement in BVAS |